GE Healthcare announced at this month's Society of Nuclear Medicine meeting the development of a system to help produce a derivative of the fluorine positron radioisotope. The 18F-F2 isotope is a critical starting point for the production of F-DOPA,
GE Healthcare announced at this month's Society of Nuclear Medicine meeting the development of a system to help produce a derivative of the fluorine positron radioisotope. The 18F-F2 isotope is a critical starting point for the production of F-DOPA, which has shown potential in diagnosing Parkinson's disease. The new technology, part of GE's PETtrace cyclotron offering, evolved from a collaboration with Imanet, a joint venture between Amersham and leading PET research centers. The 18F-F2 option boosts production capacity by nearly a factor of four, according to GE. This will increase the availability of this compound for use in research while laying the groundwork for wider use if F-DOPA becomes clinically viable.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
New Study Examines Agreement Between Radiologists and Referring Clinicians on Follow-Up Imaging
November 18th 2024Agreement on follow-up imaging was 41 percent more likely with recommendations by thoracic radiologists and 36 percent less likely on recommendations for follow-up nuclear imaging, according to new research.